Recent studies into retatruptide peptide reveal promising outlook for managing weight and type diabetes mellitus. The compound, a dual activator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, looks to offer greater body mass and glycemic regulation in contrast to existing therapies. Further research efforts are needed